Novartis Posts Lower-Than-Expected Earnings in Q4
January 27, 2016 at 07:33 AM EST
Novartis is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. Novartis’ blockbuster drug, Diovan lost exclusivity both in the U.S. and EU and entry of generics is impacting the top-line.